cbdMD (YCBD)
(Delayed Data from AMEX)
$0.49 USD
+0.02 (4.26%)
Updated Sep 27, 2024 09:55 AM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for cbdMD, Inc falls in the month of September.
All items in Millions except EPS data.
9/30/23 | 9/30/22 | 9/30/21 | 9/30/20 | 9/30/19 | |
---|---|---|---|---|---|
Sales | 24 | 35 | 44 | 42 | 24 |
Cost Of Goods | 9 | 13 | 15 | 16 | 9 |
Gross Profit | 15 | 22 | 30 | 26 | 15 |
Selling & Adminstrative & Depr. & Amort Expenses | 37 | 101 | 50 | 44 | 29 |
Income After Depreciation & Amortization | -22 | -78 | -20 | -18 | -15 |
Non-Operating Income | 0 | 8 | -5 | 29 | -33 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -23 | -70 | -24 | 11 | -48 |
Income Taxes | 0 | 0 | -1 | -1 | -2 |
Minority Interest | 0 | 0 | 0 | 0 | -1 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -23 | -70 | -23 | 13 | -45 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | -6 |
Net Income (GAAP) | -23 | -70 | -23 | 13 | -50 |
Depreciation Footnote | 9/30/23 | 9/30/22 | 9/30/21 | 9/30/20 | 9/30/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -6 | -13 | -16 | -17 | -14 |
Depreciation & Amortization (Cash Flow) | 16 | 65 | 3 | 1 | 1 |
Income After Depreciation & Amortization | -22 | -78 | -20 | -18 | -15 |
Earnings Per Share Data | 9/30/23 | 9/30/22 | 9/30/21 | 9/30/20 | 9/30/19 |
---|---|---|---|---|---|
Average Shares | 2.02 | 1.33 | 1.22 | 1.00 | 0.40 |
Diluted EPS Before Non-Recurring Items | -13.32 | -55.86 | -22.07 | 12.61 | 0.00 |
Diluted Net EPS (GAAP) | -13.32 | -55.86 | -21.17 | 12.61 | -127.03 |
Fiscal Year end for cbdMD, Inc falls in the month of September.
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 5.17 | 4.38 | 5.38 | 5.71 | 6.12 |
Cost Of Goods | 1.77 | 1.80 | 1.82 | 2.16 | 2.27 |
Gross Profit | 3.40 | 2.58 | 3.56 | 3.55 | 3.85 |
SG&A, R&D, and Dept/Amort Expenses | 3.79 | 4.13 | 4.62 | 18.77 | 5.67 |
Income After SG&A, R&D, and Dept/Amort Expenses | -0.39 | -1.55 | -1.06 | -15.22 | -1.82 |
Non-Operating Income | 0.85 | -1.44 | 0.07 | 0.00 | 0.05 |
Interest Expense | 0.01 | 0.02 | 0.00 | 0.03 | 0.00 |
Pretax Income | 0.46 | -3.01 | -1.00 | -15.87 | -1.77 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 0.46 | -3.01 | -1.00 | -15.87 | -1.77 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 0.46 | -3.01 | -1.00 | -15.87 | -1.77 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 3.59 | 2.96 | 2.96 | 2.02 | 2.38 |
Diluted EPS Before Non-Recurring Items | -0.15 | -1.35 | -0.67 | -9.06 | -1.16 |
Diluted Net EPS (GAAP) | -0.15 | -1.35 | -0.67 | -6.82 | -1.16 |